Global Non-Alcoholic Steatohepatitis (NASH) Market 2018-2025: Analysis by Drug Type and Sales Channel -- A $1.17 Billion Market in 2017, Growing to $21.47 Billion by 2025 - ResearchAndMarkets.com

August 9, 2018

DUBLIN--(BUSINESS WIRE)--Aug 9, 2018--The “Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type, and Sales Channel - Global Opportunity Analysis and Industry Forecast, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

The global non-alcoholic steatohepatitis (NASH) market was valued at $1,179 million in 2017, and is expected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients.

Key Findings

Based on drug type, the selonsertib & cenicriviroc segment is expected to exhibit the fastest market growth, is projected to grow at a CAGR of 73.7% from 2021 to 2025. Based on sales channel, the retail pharmacy segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. Based on sales channel, the online provider segment exhibited fastest growth and is anticipated to grow at a CAGR of 63.2% from 2021-2025. Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 62.62% during the forecast period.

Key Topics Covered

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview

Chapter 4: Nonalcoholic Steatohepatitis (NASH) Market, by Drug Type

Chapter 5: Nonalcoholic Steatohepatitis (NASH) Market, by Sales Channel

Chapter 6: Nonalcoholic Steatohepatitis (NASH) Market, by Region

Chapter 7: Company Profiles

Allergan PLC Cadila Healthcare Ltd. Conatus Pharmaceuticals Inc. Galmed Pharmaceuticals Ltd. Gemphire Therapeutics Inc. Genfit SA Gilead Sciences Inc. Intercept Pharmaceuticals Inc. Novartis International AG Shire PLC

For more information about this report visit https://www.researchandmarkets.com/research/sdd5mz/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180809005466/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/09/2018 09:55 AM/DISC: 08/09/2018 09:55 AM


Update hourly